Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better

被引：0

作者：

Mannucci, Pier Mannuccio ^{[1
]}

机构：

[1] Mangiagalli & Regina Elena Fdn, IRCCS Maggiore Hosp, Sci Direct, Milan, Italy

来源：

BLOOD TRANSFUSION | 2010年 / 8卷 / 04期

关键词：

VON-WILLEBRAND-FACTOR; PREVIOUSLY UNTREATED PATIENTS; INHIBITOR DEVELOPMENT; RISK-FACTORS; IN-VITRO; PRODUCTS; EPIDEMIOLOGY; ANTIBODIES; RELEVANCE; PROTECTS;

D O I：

10.2450/2010.0072.10

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：288 / 291

页数：4

共 31 条

[11] Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro -: Relevance of soluble HLA class I, soluble Fas ligand and transforming growth factor β1 [J].

Ghio, M ;

Contini, P ;

Ottonello, L ;

Arduino, N ;

Gringeri, A ;

Indiveri, F ;

Dallegri, F ;

Puppo, F .

THROMBOSIS AND HAEMOSTASIS, 2003, 89 (02) :365-373

[12] Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A [J].

Goudemand, J ;

Rothschild, C ;

Demiguel, V ;

Vinciguerrat, C ;

Lambert, T ;

Chambost, H ;

Borel-Derlon, A ;

Claeyssens, S ;

Laurian, Y ;

Calvez, T .

BLOOD, 2006, 107 (01) :46-51

[13] Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study [J].

Gouw, Samantha C. ;

van der Bom, Johanna G. ;

van den Berg, H. Marijke .

BLOOD, 2007, 109 (11) :4648-4654

[14] Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response [J].

Gringeri, A. ;

Musso, R. ;

Mazzucconi, M. G. ;

Piseddu, G. ;

Schiavoni, M. ;

Pignoloni, P. ;

Mannucci, P. M. .

HAEMOPHILIA, 2007, 13 (04) :373-379

[15] Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate [J].

Gringeri, A ;

Monzini, M ;

Tagariello, G ;

Scaraggi, FA ;

Mannucci, PM .

HAEMOPHILIA, 2006, 12 (02) :128-132

[16] Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review [J].

Iorio, A. ;

Halimeh, S. ;

Holzhauer, S. ;

Goldenberg, N. ;

Marchesini, E. ;

Marcucci, M. ;

Young, G. ;

Bidlingmaier, C. ;

Brandao, L. R. ;

Ettingshausen, C. E. ;

Gringeri, A. ;

Kenet, G. ;

Knoefler, R. ;

Kreuz, W. ;

Kurnik, K. ;

Manner, D. ;

Santagostino, E. ;

Mannucci, P. M. ;

Nowak-Goettl, U. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (06) :1256-1265

[17] von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients [J].

Kallas, A ;

Talpsep, T .

HAEMOPHILIA, 2001, 7 (04) :375-380

[18] von Willebrand factor: what is its role in the immune response in haemophilia? [J].

Kaveri, S. ;

Mannucci, P. M. ;

Kurth, M. H. ;

Ewing, N. ;

Kessler, C. M. ;

Nugent, D. J. ;

Gomperts, E. D. .

HAEMOPHILIA, 2011, 17 (01) :E235-E238

[19]

KREUZ W, 1996, ANN HEMATOL S1, V72, P339

[20] Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors [J].

Kurth, M. A. H. ;

Dimichele, D. ;

Sexauer, C. ;

Sanders, J. M. ;

Torres, M. ;

Zappa, S. C. ;

Ragni, M. ;

Leonard, N. .

HAEMOPHILIA, 2008, 14 (01) :50-55

← 1 2 3 4 →